Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Ambrosia adds a megaround for obesity drugs

 April 1, 2026

BioPharma Dive

The $100 million Series B round will be used to bring the biotech s oral GLP-1 into early human testing.

M&A / DealsMetabolic & GLP-1Read full story

Post navigation

FDA approves new high dose Spinraza regimen for SMA →
← FDA Approves First New Molecular Entity Under National Priority Voucher Program

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com